Close Menu

breach of contract

Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.

CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.

Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology. 

In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.

NEW YORK (GenomeWeb News) – Med BioGene today announced it has amended its commercialization agreement with Precision Therapeutics for Med Bio's LungExpress Dx test.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Transgenomic and Power3 Medical Products have settled a breach-of-contract suit through a mediated agreement that includes an equity-based payment, Transgenomic said today.

Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.

Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.

The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.

Transgenomic has claimed in a suit that Power3 has wrongly terminated a licensing deal between the firms, while engaging in fraud and slander.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.